Short Interest in Alzamend Neuro, Inc. (NASDAQ:ALZN) Decreases By 48.8%

Alzamend Neuro, Inc. (NASDAQ:ALZN) saw a significant decline in short interest during the month of December. As of December 31st, there was short interest totalling 32,200 shares, a decline of 48.8% from the December 15th total of 62,900 shares. Based on an average daily volume of 209,700 shares, the short-interest ratio is presently 0.2 days. Currently, 0.6% of the company’s stock are sold short.

Alzamend Neuro Price Performance

NASDAQ ALZN traded up $0.03 during trading on Wednesday, hitting $1.16. The company’s stock had a trading volume of 8,270 shares, compared to its average volume of 103,997. The business’s 50 day simple moving average is $1.26 and its 200-day simple moving average is $2.10. Alzamend Neuro has a fifty-two week low of $1.06 and a fifty-two week high of $15.06.

Analyst Upgrades and Downgrades

Separately, Ascendiant Capital Markets cut their target price on Alzamend Neuro from $35.00 to $32.00 and set a “buy” rating on the stock in a research note on Monday, December 16th.

Alzamend Neuro Company Profile

Alzamend Neuro, Inc, an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002 stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease.